A Real World Study About PMN

The investigators designed a randomized, controlled, multicenter clinical study to compare the efficacy and safety of rituximab combined with hormones versus rituximab monotherapy in the treatment of primary membranous nephropathy. At the same time, the investigators conducted a real-world study on patients who did not meet the inclusion and exclusion criteria or were unwilling to enter the RCT cohort, to further observe the trial results in a broader population.

NCT Number	NCT06893328
Lead Sponsor	Wei Chen
Conditions	Primary Membranous Nephropathy
Enrollment	200 participants
Start Date	2024-11-11
Primary Completion	2027-11-11 (estimated)
Study Completion	2027-11-11 (estimated)
Updated on ClinicalTrials.gov	2025-08-22